The market sold off Cooper Companies on the day, with the stock dropping about 15%. The decline came even as the medical device group posted Q3 revenue of US$1.066b and basic earnings per share of US$2.24, a sharp swing back into profit after a loss in Q2. The real headline is not the top line. Record free cash flow of US$273m, alongside an 11th straight non generally accepted accounting principles earnings beat, is what investors now need to weigh against the sudden reset in the share price.
Love Cooper Companies' strong free cash flow but uncomfortable with a 15% price drop on the same day? Check out the 11 resilient stocks with low risk scores for ideas that pair resilient balance sheets with more muted price swings.
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): US$1,066.2m vs. US$1,060.3m (up 0.6%)
- Net Income, Excluding Extra Items (Q3 2026 vs Q3 2025): US$432.8m vs. US$98.3m (very large increase)
- Basic EPS (Q3 2026 vs Q3 2025): US$2.24 vs. US$0.49 (very large increase)
- Free Cash Flow (Q3 2026 vs Q3 2025): US$273m vs. not disclosed (record quarterly level; comparison figure not available)
Prefer clear visual charts to dense tables of figures? See Cooper Companies' full financial picture, including a concise view of its valuation in the company report for Cooper Companies.
Cooper Companies bull case meets mixed reality
Bulls argue Cooper Companies can turn premium lenses, myopia control and fertility into a steady earnings and free cash flow machine. Parts of that script are playing out. MyDay consumption is growing at a double digit pace in EMEA and the Americas, while MiSight is up about 20% organically year to date and fertility revenue is rising about 5% with broad product strength. Record quarterly free cash flow of US$273m and an 11th straight non GAAP EPS beat show the operating model can convert sales into cash. Yet top line progress is muted, with group revenue up about 1% and CooperVision roughly flat as U.S. channel destocking and legacy hydrogel rationalization offset premium lens momentum. The bull view on mix and efficiency is partially validated, but the milestone of clear, accelerating organic growth across the portfolio is not hit this quarter.
Bearish worries on growth and volatility resurface
Critics focus on slowing momentum, uneven fertility demand and execution risk in Asia Pacific and myopia control. The latest quarter gives them fresh talking points. Headline revenue is growing only about 1%, Q4 guidance implies flat to slightly negative organic sales at CooperVision, and Asia Pacific including China is still a drag despite MiSight leadership globally. The fertility franchise is improving, yet CooperSurgical is only advancing about 3% organically, so operating leverage remains limited at the group level. The decision to keep CooperSurgical after a review, plus a larger buyback, suggests management sees long term value, but the immediate share price reaction, with the stock down about 15% on the day and roughly 29% over 30 days, shows investors are treating execution and guidance cuts as real risks rather than noise.
Compare Cooper Companies' operational rebound, with record free cash flow and recurring non GAAP EPS beats, with the recent 15% one day share price drop that has reset expectations by checking the consensus price target analysis for Cooper Companies.Stay Ahead Of Your Next Move
Cooper Companies just paired record free cash flow with a sharp 15% one day share price drop, which is exactly the kind of setup you may want to track closely by registering for free with Simply Wall St and adding it to your Watchlist to watch price against fair value for a potential entry point. After you commit capital, keep the noise down and the signals clear by managing everything through your Portfolio Command Center. This way, you see only the most relevant updates on your holdings. For a longer view, tap into what other investors are seeing and debating through the Community and put that crowd insight alongside your own work. That combination can help you identify catalysts and risks early so you can stay ahead of the market instead of reacting to it late.
Seeking Alternatives Beyond Cooper Companies?
Fresh ideas move first. Breakout stories and dropping valuations rarely stay under the radar for long before the crowd piles in and momentum flies away, so act now.
- Spot potential breakout compounders early by scanning curated 17 high quality undiscovered gems that are still flying under most radars but already building real business traction.
- Target stability with purpose by reviewing a hand picked list of solid balance sheet and fundamentals stocks (24 results) that can help you stay invested when volatility spikes.
- Ride structural tailwinds in critical materials by checking a vetted list of 30 best rare earth metal stocks before capital floods into the same limited set of opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com